Literature DB >> 35292343

Structure-activity relationship studies of functionalized aromatic peptidomimetics as neurolysin activators.

Md Shafikur Rahman1, Shiva Hadi Esfahani2, Saeideh Nozohouri2, Shikha Kumari1, Joanna Kocot2, Yong Zhang2, Thomas J Abbruscato3, Vardan T Karamyan3, Paul C Trippier4.   

Abstract

Modulating peptidase neurolysin (Nln) has been identified as a potential cerebroprotective target for the development of therapeutics for ischemic stroke. Continued structure-activity relationship studies on peptidomimetic small molecule activators of Nln bearing electron-donating and electron- withdrawing functionalized phenyls are explored. Incorporation of fluorine or trifluoromethyl groups produces Nln activators with enhanced A50, while methoxy substitution produces derivatives with enhanced Amax. Selected activators containing methoxy or trifluoromethyl substitution are selective for Nln over related peptidases and possess increased blood-brain barrier penetrability than initial hits.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blood–brain barrier; Electron-donating; Electron-withdrawing; Neurolysin activators; Peptidases

Mesh:

Substances:

Year:  2022        PMID: 35292343      PMCID: PMC8985228          DOI: 10.1016/j.bmcl.2022.128669

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

1.  Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sandeep R Das; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Carmen R Isasi; Monik C Jiménez; Suzanne E Judd; Brett M Kissela; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David J Magid; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Wayne Rosamond; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2015-12-16       Impact factor: 29.690

Review 2.  Intravenous thrombolytics for ischemic stroke.

Authors:  Andrew D Barreto
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

3.  Peptidase neurolysin is an endogenous cerebroprotective mechanism in acute neurodegenerative disorders.

Authors:  Vardan T Karamyan
Journal:  Med Hypotheses       Date:  2019-07-13       Impact factor: 1.538

Review 4.  Selecting Good 'Drug-Like' Properties to Optimize Small Molecule Blood-Brain Barrier Penetration.

Authors:  Paul C Trippier
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 5.  Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.

Authors:  Joachim Röther; Gary A Ford; Vincent N S Thijs
Journal:  Cerebrovasc Dis       Date:  2013-04-23       Impact factor: 2.762

Review 6.  Lipophilic Efficiency as an Important Metric in Drug Design.

Authors:  Ted W Johnson; Rebecca A Gallego; Martin P Edwards
Journal:  J Med Chem       Date:  2018-04-17       Impact factor: 7.446

Review 7.  Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives.

Authors:  Diji Kuriakose; Zhicheng Xiao
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

8.  The Incidence and Mortality Ratio of Ischemic Cerebrovascular Accidents in COVID-19 Cases: A Systematic Review and Meta-Analysis.

Authors:  Sina Parsay; Armin Vosoughi; Aytak Khabbaz; Saeed Sadigh-Eteghad
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-12-17       Impact factor: 2.136

9.  The role of peptidase neurolysin in neuroprotection and neural repair after stroke.

Authors:  Vardan T Karamyan
Journal:  Neural Regen Res       Date:  2021-01       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.